🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead

Published 10/30/2024, 03:50 PM
Updated 10/30/2024, 09:25 PM
© Reuters. FILE PHOTO: U.S. flag and Judge gavel are seen in this illustration taken, August 6, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
RKT
-
ABT
-

By Brendan Pierson

(Reuters) -A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies' formulas for premature babies caused a severe intestinal illness.

Litigation over the formulas has raised alarm from doctors who say it could threaten the formulas' availability or affect medical decisions.

Abbott CEO Robert Ford (NYSE:F) has told investors that it may pull its premature infant formula from the market because of the litigation. Reckitt in July said it was "considering options" for Mead Johnson, and CEO Kris Licht did not rule out a sale.

"Companies have to clearly and unambiguously tell us the truth about their products, especially those intended for the smallest and most vulnerable human beings on the planet," Tim Cronin, representing Elizabeth Whitfield and her son Kaine, told the jury in St. Louis, Missouri, in his closing argument at the end of a five-week trial.

Cronin said the companies failed to warn that their premature baby formulas could cause necrotizing enterocolitis, and that Kaine got the disease as a result of receiving the formula in the newborn intensive care unit at St. Louis Children's Hospital in 2017, leaving him with lifelong health and developmental problems.

Cronin asked the jury to award Kaine nearly $277 million in compensatory damages for his past and future healthcare costs, lost earning potential and pain and suffering. He also urged them to order Abbott to pay $5 billion in punitive damages, and Mead Johnson to pay $1 billion, based on the companies' sizes.

Both companies have said that, while mother's and donated human milk is widely understood to protect against necrotizing enterocolitis, formula does not cause it.

Rebecca Fitzpatrick, a lawyer for Abbott, told jurors in her closing statement that formula could not have caused Kaine's illness because it was used only to "top off" his mother's milk. She said Kaine had numerous other risk factors, including anemia and infections treated with antibiotics, that greatly increased his chances of getting the disease.

"Kaine simply would have gotten (necrotizing enterocolitis) no matter what he was fed," she said.

The verdict Whitfield is seeking would be one of the largest in U.S. history. Even if the jury awards it, however, it could be reduced on appeal for a number of reasons, including that the U.S. Supreme Court has ruled that punitive damages should generally be less than 10 times compensatory damages.

While the hospital was also a defendant in the case, Cronin did not ask the jurors to award any damages against it, though he said they were free to do so.

Reuters watched the closing argument through Courtroom View Network.

© Reuters. FILE PHOTO: U.S. flag and Judge gavel are seen in this illustration taken, August 6, 2024. REUTERS/Dado Ruvic/Illustration/File Photo

Whitfield's case is one of close to 1,000 in courts around the United States alleging that Abbott's and Mead's specialized formulas used by hospitals to feed premature babies cause the illness. Two cases that previously went to trial resulted in verdicts of $60 million against Mead and $495 million against Abbott.

Following the earlier verdicts, U.S. regulatory agencies and a working group of scientists convened by the National Institutes of Health have said current evidence does not support the hypothesis that formula causes necrotizing enterocolitis. Abbott and Mead were not allowed to present those statements to the jury in the current trial.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.